Taiho Pharmaceutical Co., Ltd. entered into a definitive agreement to acquire Araris Biotech AG, a Swiss biotechnology company developing next-gen antibody drug conjugates (ADCs), for $400 million at closing, with the potential for additional milestone payments of up to $740 million. The acquisition follows a research collaboration between the companies signed in November 2023. Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and pioneering the development of best-in...